文献速递肾小球疾病

因子H相关蛋白1升高及因子H致病性变异降低IgA肾病补体调节功能

Elevated factor H-related protein 1 and factor H pathogenic variants decrease complement regulation in IgA nephropathy.
PubMed 文献 · Kidney Int · 2017-06-19

该研究在112例IgA肾病、46例常染色体显性多囊肾病和76例对照中分析因子H与FHR-1水平,发现IgA肾病患者FHR-1及FHR-1/FH比值异常升高,且疾病进展者最高;ΔCFHR3-CFHR1纯合子对IgA肾病有保护作用,部分IgA肾病患者携带CFH或CFI致病性变异,提示FHR-1与FH竞争及FH活性下降参与IgA肾病补体调节异常。

要点

  • IgA肾病患者FHR-1水平及FHR-1/FH比值较对照升高,疾病进展者最高。
  • ΔCFHR3-CFHR1纯合子对IgA肾病有保护作用,对ADPKD无保护作用。
  • 部分IgA肾病患者携带CFH或CFI致病性变异,提示FH活性下降。

核心结论

  • IgA肾病中因FHR-1/FH竞争增加或CFH致病性变异导致FH活性下降。
  • 肾功能恶化升高FHR-1水平,可能形成旁路补体激活的恶性循环。

研究设计与样本

  • 研究纳入112例IgA肾病患者、46例非补体相关常染色体显性多囊肾病患者和76例对照个体。

主要发现

  • IgA肾病和ADPKD患者FH水平正常,但FHR-1水平及FHR-1/FH比值较对照异常升高。
  • IgA肾病疾病进展者和已进展至慢性肾脏病的ADPKD患者FHR-1水平及FHR-1/FH比值最高。
  • ΔCFHR3-CFHR1纯合子对IgA肾病有保护作用,但对ADPKD无保护作用。
  • 发现5例IgA肾病患者携带CFH或CFI致病性变异且FH水平低。

临床怎么用

  • 监测IgA肾病患者FHR-1/FH比值可能有助于评估补体调节异常和疾病进展风险。
  • 对IgA肾病患者可考虑筛查CFH和CFI致病性变异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IgA nephropathy (IgAN), a frequent cause of chronic kidney disease worldwide, is characterized by mesangial deposition of galactose-deficient IgA1-containing immune complexes. Complement involvement in IgAN pathogenesis is suggested by the glomerular deposition of complement components and the strong protection from IgAN development conferred by the deletion of the CFHR3 and CFHR1 genes (ΔCFHR3-CFHR1). Here we searched for correlations between clinical progression and levels of factor H (FH) and FH-related protein 1 (FHR-1) using well-characterized patient cohorts consisting of 112 patients with IgAN, 46 with non-complement-related autosomal dominant polycystic kidney disease (ADPKD), and 76 control individuals. Patients with either IgAN or ADPKD presented normal FH but abnormally elevated FHR-1 levels and FHR-1/FH ratios compared to control individuals. Highest FHR-1 levels and FHR-1/FH ratios are found in patients with IgAN with disease progression and in patients with ADPKD who have reached chronic kidney disease, suggesting that renal function impairment elevates the FHR-1/FH ratio, which may increase FHR-1/FH competition for activated C3 fragments. Interestingly, ΔCFHR3-CFHR1 homozygotes are protected from IgAN, but not from ADPKD, and we found five IgAN patients with low FH carrying CFH or CFI pathogenic variants. These data support a decreased FH activity in IgAN due to increased FHR-1/FH competition or pathogenic CFH variants. They also suggest that alternative pathway complement activation in patients with IgAN, initially triggered by galactose-deficient IgA1-containing immune complexes, may exacerbate in a vicious circle as renal function deterioration increase FHR-1 levels. Thus, a role of FHR-1 in IgAN pathogenesis is to compete with complement regulation by FH.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Tortajada A, Gutiérrez E, Goicoechea de Jorge E, et al. Elevated factor H-related protein 1 and factor H pathogenic variants decrease complement regulation in IgA nephropathy. Kidney Int. 2017. PMID: 28637589. doi:10.1016/j.kint.2017.03.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。